Filing Flows › Health Care › Rani Therapeutics Holdings (RANI)
Rani Therapeutics Holdings (RANI) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 13, 2026 · Rani Therapeutics Holdings (RANI) Q2 2026 earnings results →
Q2 2026 493¢ of every $1 of revenue lost · operating margin -516.9%
Rani Therapeutics Holdings made $1.7M in Q2 2026. Operating margin -516.9%, net loss $8.4M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 13, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $1.7M in Q2 2026, roughly flat from the previous quarter.
Operating costs exceeded revenue by $8.8M, an operating margin of -516.9%. The quarter ended with a net loss of $8.4M, wider than the previous quarter's $8.0M loss. Minority interests bore $1.0M of it: to shareholders the quarter was a loss of $7.4M.
Operating cash flow was −$9.0M. Non-cash charges added back $152K of depreciation and amortization and $2.4M of share-based compensation. Working capital and other items used $3.2M. Capital expenditures of $32K exceeded it, leaving free cash flow of −$9.1M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 13, 2026 | $1.7M | — | -516.9% | −$8.4M | −$9.0M |
| Q1 2026 | 10-Q | May 15, 2026 | $1.7M | +893% | -488.2% | −$8.0M | −$6.5M |
| Q4 2025 | 10-K | Mar 26, 2026 | $1.5M | +42% | -584.2% | −$9.1M | $294K |
| Q1 2025 | 10-Q | May 13, 2025 | $172K | — | n/m | −$12.7M | −$8.1M |
| Q4 2024 | 10-K | Mar 31, 2025 | $1.0M | — | n/m | −$15.7M | −$8.7M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Rani Therapeutics Holdings
We are a clinical stage biotherapeutics company focusing on advancing technologies to enable the administration of biologics and drugs orally, to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. We are advancing a portfolio of oral therapeutics using our proprietary delivery technology and we are actively pursuing partnering the technology with third party biopharmaceutical companies for the oral delivery of their biologics and drugs. Our technology comprises a drug-agnostic oral delivery platform, the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. We have two configurations of the platform – the RaniPill GO and the RaniPill HC.
In its own words, from its 10-K, filed Mar 26, 2026.
Rani Therapeutics Holdings against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Operating margin: -516.9% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| RANI Rani Therapeutics Holdings | Q2 2026 | $1.7M | — | -516.9% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Rani Therapeutics Holdings 10-Q on SEC EDGAR · CIK 1856725 · Pharmaceutical Preparations
13F: who owns RANI and who is buying
More on RANI
- How Rani Therapeutics Holdings makes money: revenue by segment
- Rani Therapeutics Holdings next earnings date and what analysts expect
- Rani Therapeutics Holdings stock forecast, price target and fair value
- Who owns Rani Therapeutics Holdings stock: holders, funds and Congress trades
- Rani Therapeutics Holdings recalls, complaints and regulation
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q1 2025 results · Q4 2024 results